Brentuximab vedotin

Drugs in R and D

Volumn 11, Issue 1, 2011, Pages 85-95

[No Author Info available]

Author keywords

Brentuximab vedotin; general; Hodgkins disease; Research and development; treatment

Indexed keywords

ANTINEOPLASTIC AGENT; AURISTATIN E; BLEOMYCIN; BRENTUXIMAB VEDOTIN; DACARBAZINE; DOXORUBICIN; GEMCITABINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD30; NAVELBINE; PLACEBO; UNCLASSIFIED DRUG; VINBLASTINE;

ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG COST; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; FATIGUE; FEBRILE NEUTROPENIA; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; INJECTION SITE IRRITATION; LARGE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MICROTUBULE ASSEMBLY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; NORTH AMERICA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATITIS; SENSORY NEUROPATHY; SEPSIS; SINGLE DRUG DOSE; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 79953146631     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.2165/11591070-000000000-00000     Document Type: Article

References (37)

1. Seattle Genetics, Inc., Millennium: The Takeda Oncology Company, Takeda Pharmaceutical Company Limited. Seattle Genetics, Inc., Millennium: The Takeda Oncology Company, announce strategic collaboration for novel late stage lymphoma program brentuximab vedotin (SGN-35). www.takeda.com, 15 Dec. 2009 Media Release
2. Seattle Genetics, Inc. Seattle Genetics Establishes Preferred Antibody-Drug Conjugate Manufacturing Relationship with Albany Molecular Research, Inc. www.seattlegen etics.com, 13 Jul. 2004 Media Release
3. Seattle Genetics, Inc. Seattle Genetics Launches Manufacturing Campaign with Albany Molecular Research. www.seattlegenetics.com, 05 May 2005 Media Release
4. Seattle Genetics, Inc, Millennium: The Takeda Oncology Company. Seattle Genetics and Millennium Report Positive Data from Phase II Trial of Brentuximab Vedotin (SGN-35) in Relapsed or Refractory ALCL at ASH Annual Meeting. www.takeda.co.jp, 07 Dec. 2010 Media Release
5. Seattle Genetics, Inc. Seattle Genetics Receives Orphan Drug Designations for SGN-35 in the United States and Europe. www.seattlegenetics.com, 27 Jan 2009 Media Release
6. Seattle Genetics, Inc. Seattle Genetics Receives Orphan Drug Designations for its SGN-33 and SGN-35 Programs. www.seattlegenetics.com, 14 Feb. 2007 Media Release
7. Seattle Genetics, Inc. Seattle Genetics Receives FDA Fast Track Designation for SGN-35 for the Treatment of Hodgkin Lymphoma. www.seattlegenetics.com, 31 Mar. 2009 Media Release
8. Seattle Genetics, Inc., Takeda Pharmaceutical Company Limited, Millennium: The Takeda Oncology Company. Seattle Genetics, Takeda and Millennium Announce Initiation of Phase III AETHERA Trial of Brentuximab Vedotin (SGN-35) for Post-Transplant Hodgkin Lymphoma. www.seattlegenetics.com, 08 Apr. 2010 Media Release
9. Seattle Genetics, Inc. Seattle Genetics and Millennium Report Positive Data from Pivotal Trial of Brentuximab Vedotin (SGN-35) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting. www.seattlegene tics.com, 06 Dec. 2010 Media Release
10. Seattle Genetics, Inc, Millennium: The Takeda Oncology Company. Seattle Genetics and Millennium Announce Positive Top-Line Brentuximab Vedotin (SGN-35) Data from Pivotal Trial in Relapsed and Refractory Hodgkin Lymphoma. www.seattlegenetics.com, 27 Sep. 2010 Media Release
11. Seattle Genetics, Inc. Seattle Genetics Initiates Brentuximab Vedotin (SGN-35) Retreatment Clinical Trial. www.seat tlegenetics.com, 25 Jul. 2009 Media Release
12. Seattle Genetics, Inc. Seattle Genetics Reports Strong Pipeline Progress and Second Quarter 2009 Financial Results. www.seagen.com, 24 Jul. 2009 Media Release
13. Seattle Genetics, Inc, Millennium Pharmaceuticals Inc. Seattle Genetics and Millennium Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma. www.seattlegenetics.com, 04 Feb. 2010 Media Release
14. Seattle Genetics, Inc, Millennium. Seattle Genetics and Millennium Announce Positive Top-Line Brentuximab Vedotin (SGN-35) Data from Phase II Trial in Relapsed or Refractory ALCL. www.seattlegenetics.com, 11 Oct. 2010 Media Release
15. Seattle Genetics, Inc, Millennium: The Takeda Oncology Company. Seattle Genetics and Millennium Complete Enrollment of Brentuximab Vedotin (SGN-35) Phase II ALCL Trial. www.seattlegenetics.com, 24 May 2010 Media Release
16. Seattle Genetics, Inc. Seattle Genetics Initiates Phase II Trial of SGN-35 for Anaplastic Large Cell Lymphoma. www.seattlegenetics.com, 19 Jun. 2009 Media Release
17. Seattle Genetics, Inc. Seattle Genetics Reports Development Progress and Third Quarter 2008 Financial Results. www.seattlegenetics.com, 24 Oct. 2008 Media Release
18. Seattle Genetics, Inc. Seattle Genetics Reports Durable Objective Responses with SGN-35 in Lymphoma. www.seat tlegenetics.com, 07 Dec. 2008 Media Release
19. Seattle Genetics, Inc. Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate Programs. www.seat tlegenetics.com, 25 Oct. 2008 Media Release
20. Seattle Genetics, Inc. Seattle Genetics Reports Positive Phase I Data with SGN-35 in Hodgkin Lymphoma. www.seattlegenetics.com, 06 Nov. 2007 Media Release
21. An Intensive QT/QTc Study to Investigate the Effects of SGN-35 (Brentuximab Vedotin) on Cardiac Ventricular Repolarization in Patients With CD30-Positive Malignancies. Clinical Trial Profile
22. Fanale M, Bartlett NL, Forero-Torres A, et al. The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study. 51st Annual Meeting and Exposition of the American Society of Hematology: abstr. 2731, 5 Dec. 2009. Available from URL: http://www.he matology.org [English]
23. Seattle Genetics, Inc. Seattle Genetics Reports Data from a Weekly Dosing Phase I Clinical Trial of SGN-35 in Lymphoma. www.seattlegenetics.com, 02 Jun. 2009 Media Release
24. Seattle Genetics, Inc. Seattle Genetics Expands SGN-35 Clinical Program with Initiation of Second Phase I Trial. www.seattlegenetics.com, 29 Mar. 2008 Media Release
25. Seattle Genetics, Inc. Seattle Genetics Expands Antibody-Drug Conjugate Patent Portfolio. www.seattlegenetics.com, 12 Mar. 2010 Media Release
26. Seattle Genetics, Inc. Seattle Genetics Reports Positive Data from Phase IWeekly-Dosing Clinical Trial of Brentuximab Vedotin (SGN-35) in Lymphoma. www.seattlegenetics.com, 08 Dec. 2009 Media Release
27. Younes A, Forero-Torres A, Bartlett NL, et al. Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma. 44th Annual Meeting of the American Society of Clinical Oncology: abstr. 8526, 30 May 2008. Available from URL: http://www.asco.org [English]
28. Francisco JA, Cerveny CG, Meyer DL, et al. SGN-35, an anti-CD30 antibody-drug conjugate with potent antitumor activity. 94th Annual Meeting of the American Association for Cancer Research: 149 (plus poster) abstr. R770, 11 Jul. 2003. USA [English]
29. Seattle Genetics, Inc. Seattle Genetics Reports Data from SGN-35 Every Three Week Dosing Phase I Trial in Lymphoma. www.seattlegenetics.com, 08 Jun. 2009 Media Release
30. Seattle Genetics, Inc. Seattle Genetics Reports Multiple Complete and Partial Responses with SGN-35 in Patients with Lymphoma. www.seattlegenetics. com, 04 Jun. 2008 Media Release
31. Seattle Genetics, Inc, Millennium: The Takeda Oncology Company. Seattle Genetics and Millennium Report Positive Data on Retreatment with Brentuximab Vedotin (SGN-35) in Lymphoma. www.seagen.com, 08 Jun. 2010 Media Release
32. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin e conjugate with potent and selective antitumor activity. Blood 2003;102(4):1458-65. USA [English] (Pubitemid 36988057)
33. Seattle Genetics Inc. Seattle Genetics Presents Data from SGN-35 Program at International Conference on Malignant Lymphoma. www.seattlegenetics.com, 10 Jun. 2005 Media Release
34. Barton J, Hamblett K, Cerveny C, et al. The anti-CD30 antibody-drug conjugate SGN-35 is a potent therapy for the treatment of CD30+ malignancies. Annals of Oncology 2005;16(Suppl. 5):134. USA [English]
35. Gerber HP, Oflazoglu E, Kissler K, et al. Combination of the anti-CD30-auristatin-E antibody-drug conjugate SGN-35 with chemotherapy improves antitumor activity in Hodgkin lymphoma. 20th-EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics: 166 abstr. 523, 24 Oct. 2008. Available from URL: http://www.ecco-org.eu USA [English]
36. Seattle Genetics, Inc. Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate Programs at AACR. www.seattlegenetics.com, 23 Apr. 2009 Media Release
37. American Society of Hematology. New Standards of Care and Novel Treatment Options for Several Forms of Lymphoma Unveiled. www.hematology.org, 06 Dec. 2010 Media Release